Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

55X_ROI_Q1_2026 Jun. 23 at 6:42 PM

$SLS $ABBV SLS Share Price, Market Value, Institutional Funds Invested, Cash on Hand; all up 4x-12x since the IDMC Unblinded Actual MOS and IR data from the Interim Analysis. - smart money knows For anyone seriously interested in a heavy Investment, do some due diligence on BAT survival*. There are 100 trials, with all the so called Youngest, Healthiest, Most Select Patients getting into a Second remission CR2 - and there is NIL SURVIVAL past 18/20 months, absent transplant. Including all In trial Patients… We have at least 47 of 126 alive at least 26 months. 43 of them at least 27 39 at least 28 35 at least 29 31 30 28 31 25 32 * link to many many BAT published trials

0 · Reply

Scanlz Jun. 23 at 2:36 PM

$ABBV i first purchase this stock when it was over $90

0 · Reply

VeltrixCapitalOfficial Jun. 23 at 2:28 PM

SUPER HIGH CONFIDENCE 🚨 6/26 $ABBV 250c @.18 1000 CONTRACTS

0 · Reply

Quantumup Jun. 23 at 1:22 PM

Canaccord⬆️ $ABBV-$273, reit Buy/said: ABBV's acquisition of $APGE for ~$10.1B net makes very good strategic sense adding a potential mega-blockbuster Immunology asset for AD/asthma that should be a major growth driver in the next decade. KYMR CRVS ORKA REGN - SNY $LLY Here's what else Canaccord Genuity had to say: https://x.com/Quantumup1/status/2069410413242921075?s=20

0 · Reply

OpenOutcrier Jun. 23 at 12:38 PM

$ABBV (+0.6% pre) EU approves AbbVie's Skyrizi for children with plaque psoriasis https://ooc.bz/l/105847

0 · Reply

Quantumup Jun. 23 at 12:12 PM

H.C. Wainwright reiterated $ORKA Buy-$120 UCBJY JNJ - PTGX ALMS TAK H.C. Wainwright commented on y'day's $APGE and $ABBV M&A deal, pointing to Apogee's similarity to Oruka, as it was incepted by privately-held Paragon Therapeutics, and additionally said: In our view, Oruka and Apogee have many points of commonality, including a focus on I&I (particularly inflammatory skin diseases) and the intent to advance investigational agents with best-in-disease potential. We reiterate our Buy rating and 12-month price target of $120 per share.

0 · Reply

IonicUnuntrium Jun. 23 at 11:15 AM

$SNDK just rotate to healthcare $LNTH $ABBV $UNH

0 · Reply

IonicUnuntrium Jun. 23 at 11:14 AM

$SPY $LNTH and $ABBV cookin. Healthcare is safety

0 · Reply

IonicUnuntrium Jun. 23 at 11:13 AM

$QQQ $LNTH and $ABBV lookin better than most rn 👀

0 · Reply

IonicUnuntrium Jun. 23 at 11:12 AM

$MU only healthcare is safe $LNTH $VEEV $ABBV

0 · Reply

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

2026-06-23T12:22:00.000Z - 6 hours ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

APGE

Jun 23, 2026, 8:00 AM EDT - 7 hours ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

2026-06-23T11:29:50.000Z - 7 hours ago

Apogee Therapeutics moved to No Rating at BofA

APGE

2026-06-23T11:04:51.000Z - 8 hours ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE

2026-06-23T10:24:35.000Z - 8 hours ago

AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:00:54.000Z - 9 hours ago

AbbVie announces European Commission approval of Maviret

2026-06-23T09:46:03.000Z - 9 hours ago

AbbVie announces EU approval of Skyrizi for pediatric patients

Jun 23, 2026, 5:00 AM EDT - 10 hours ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 3:00 AM EDT - 12 hours ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

2026-06-22T21:55:09.000Z - 21 hours ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

APGE EVMN

Jun 22, 2026, 10:30 AM EDT - 1 day ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

Jun 22, 2026, 10:15 AM EDT - 1 day ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

Jun 22, 2026, 9:00 AM EDT - 1 day ago

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 1 day ago

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 1 day ago

AbbVie Press release: M&A announcement

2026-06-22T12:24:03.000Z - 1 day ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

APGE REGN

Jun 22, 2026, 7:42 AM EDT - 1 day ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

2026-06-22T11:15:52.000Z - 1 day ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

APGE

2026-06-22T11:10:51.000Z - 1 day ago

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

APGE

Jun 22, 2026, 7:06 AM EDT - 1 day ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

Jun 22, 2026, 7:04 AM EDT - 1 day ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

Jun 22, 2026, 7:00 AM EDT - 1 day ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

2026-06-22T10:48:07.000Z - 1 day ago

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

APGE CLDX CNTB EVMN KYMR NKTR

2026-06-22T10:40:59.000Z - 1 day ago

BTIG says others may be interested in Apogee Therapeutics

APGE CBIO JBIO JNJ NVS ORKA PFE

2026-06-22T10:23:29.000Z - 1 day ago

AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo

APGE REGN

2026-06-22T09:00:15.000Z - 1 day ago

AbbVie near deal to acquire Apogee Therapeutics, FT reports

APGE

2026-06-22T05:55:55.000Z - 1 day ago

‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition

APGE REGN SNY

Jun 20, 2026, 12:11 PM EDT - 3 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

2026-06-19T17:25:03.000Z - 4 days ago

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

APGE

Jun 19, 2026, 11:17 AM EDT - 4 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

Jun 18, 2026, 4:05 PM EDT - 4 days ago

AbbVie Declares Quarterly Dividend

Jun 16, 2026, 8:00 AM EDT - 7 days ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 12, 2026, 3:00 AM EDT - 11 days ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 11, 2026, 7:14 AM EDT - 12 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

Jun 10, 2026, 11:47 AM EDT - 13 days ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 9, 2026, 10:40 AM EDT - 14 days ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 15 days ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 3, 2026, 7:04 PM EDT - 19 days ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 3:30 AM EDT - 20 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

Jun 2, 2026, 8:00 AM EDT - 21 days ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 29, 2026, 8:00 AM EDT - 25 days ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 27, 2026, 6:18 PM EDT - 26 days ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 3:33 PM EDT - 26 days ago

US FDA approves AbbVie's rare blood cancer drug

May 22, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 21, 2026, 6:46 PM EDT - 4 weeks ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 4:10 PM EDT - 4 weeks ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 13, 2026, 2:20 PM EDT - 5 weeks ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 10:00 AM EDT - 6 weeks ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 5, 2026, 8:05 AM EDT - 7 weeks ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

May 1, 2026, 3:05 PM EDT - 7 weeks ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 7 weeks ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 7 weeks ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 9:00 AM EDT - 7 weeks ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 7 weeks ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 7:50 AM EDT - 7 weeks ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 7 weeks ago

AbbVie Reports First-Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 2 months ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 2 months ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 2 months ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 2 months ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 2 months ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:02 PM EDT - 2 months ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 20, 2026, 2:30 AM EDT - 2 months ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 14, 2026, 8:50 AM EDT - 2 months ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 13, 2026, 2:24 AM EDT - 2 months ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 12, 2026, 7:15 AM EDT - 2 months ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 8, 2026, 1:38 PM EDT - 2 months ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 8:00 AM EDT - 2 months ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 7, 2026, 9:53 AM EDT - 2 months ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

55X_ROI_Q1_2026 Jun. 23 at 6:42 PM

0 · Reply

Scanlz Jun. 23 at 2:36 PM

$ABBV i first purchase this stock when it was over $90

0 · Reply

VeltrixCapitalOfficial Jun. 23 at 2:28 PM

SUPER HIGH CONFIDENCE 🚨 6/26 $ABBV 250c @.18 1000 CONTRACTS

0 · Reply

Quantumup Jun. 23 at 1:22 PM

0 · Reply

OpenOutcrier Jun. 23 at 12:38 PM

$ABBV (+0.6% pre) EU approves AbbVie's Skyrizi for children with plaque psoriasis https://ooc.bz/l/105847

0 · Reply

Quantumup Jun. 23 at 12:12 PM

0 · Reply

IonicUnuntrium Jun. 23 at 11:15 AM

$SNDK just rotate to healthcare $LNTH $ABBV $UNH

0 · Reply

IonicUnuntrium Jun. 23 at 11:14 AM

$SPY $LNTH and $ABBV cookin. Healthcare is safety

0 · Reply

IonicUnuntrium Jun. 23 at 11:13 AM

$QQQ $LNTH and $ABBV lookin better than most rn 👀

0 · Reply

IonicUnuntrium Jun. 23 at 11:12 AM

$MU only healthcare is safe $LNTH $VEEV $ABBV

0 · Reply

DonCorleone77 Jun. 23 at 11:11 AM

$ABBV AbbVie announces EU approval of Skyrizi for pediatric patients AbbVie announced that the European Commission has approved SKYRIZI for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy. The approval includes a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg. The EC's approval of SKYRIZI in pediatric patients is supported by clinical data from the Phase 3 OptIMMize-1 pediatric psoriasis program, including data from two lead-in pharmacokinetic cohorts: a randomized efficacy assessor-blinded, active-controlled cohort, and a single-arm, open-label cohort, in addition to the Phase 3 OptIMMize-2 open-label extension study. The safety profile in pediatric patients treated with SKYRIZI was consistent with that observed in adults with moderate to severe plaque psoriasis, with no new safety signals observed.

0 · Reply

55X_ROI_Q1_2026 Jun. 23 at 6:45 AM

$SLS BAT is toxic, even deadly, recently failed 3 Phase 3 Trials conducted by $ABBV They KNOW Gps is the only reason we are seeing extended Survival in the REGAL Trial.

0 · Reply

StockVisionn Jun. 23 at 5:16 AM

$ABBV is part of my institutional accumulation signal thesis. Risk is managed, and I am letting time do the work.

0 · Reply

SellasgpsCurativeBAT11 Jun. 23 at 3:59 AM

$BMY $PFE $SLS $JNJ 4. My # 1 Suitor for Sellas remains Pfizer followed by close 2nd $BMY 3rd $ABBV and 4Th $JNJ ✌️🙏❤️‍🩹 While Pfizer has made all the right moves in preparation of Sellas BO in January 2026 Pfizer appointed Michael Burns brother of SLS CFO John Burns as Senior Medical Director of Oncology Late Development, coming directly from oncology early development at AbbVie. Someone who spent their career in the belly of the beast understanding exactly how AbbVie develops oncology assets, exactly where the gaps in the Venetoclax franchise are, and exactly what kind of validated late stage asset Pfizer needs to compete in hematologic malignancies just walked through Pfizer's door. Dr. Angelos Stergiou has directly called out Unlike Onureg, GPS does not suppress the bone marrow. This is a critical advantage for AML patients who already have fragile blood counts. AbbVie will be the biggest looser and Ventoclax will be Obsolete. JNJ BOD Katherine Bach connection is compelling. P1 ✌️🙏❤️‍🩹

1 · Reply

RunnerSignals Jun. 23 at 3:25 AM

$SMCI $GOOG $LCID $ABBV $ACA Late Night Market Recap Stocks Making the Biggest Moves https://stocksrunner.com/news/2026-06-22-late-night-market-recap-stocks-making-the-biggest-moves

0 · Reply

StocktwitsNews Jun. 23 at 3:04 AM

Why Did INTC, KEEL, APGE Stocks Hit 52-Week Highs Today? $INTC $KEEL $APGE $ABBV https://stocktwits.com/news/equity/markets/why-did-intc-keel-apge-stocks-hit-52-week-highs-today/cZKv8wrR790

0 · Reply

MomentumCapitall Jun. 23 at 2:51 AM

$ABBV $SOFI $QS $DKNG is trading in a way that reflects AI momentum continuation. I am staying disciplined and letting the chart confirm the narrative.

0 · Reply

SellasgpsCurativeBAT11 Jun. 23 at 2:28 AM

$SLS $ABBV $PFE $PFE I am more excited about the bidding war behind the scenes than ever before because in last few months We have seen a floor set for a bare minimum single potential Blockbuster phase 3 drug asset at $10 Billion. What are the true implications of an Oncology Platforms that can tackle 40+ different cancer types with an unprecedented Ad Infinitum Dosage schedule for 3 plus year with CURATIVE outcome? First comes the Trigger 80Th event that triggers the Top line data for Regal Pivotal Registrational phase 3. My Long Brothers and Sisters I have moved past charting and modeling scenarios to final valuation of this juggernaut unfolding right before our own eyes. Be encouraged by what’s going on in the Biotechnology sector. Last week we saw 10 deals. First day of the week today, We already saw the biggest acquisition by AbbVie in an over a decade. SLS Valuation will Top $50 Billion when the bidding war is over. Mark this post, it’s coming sooner than you all think ✌️🙏❤️‍🩹

1 · Reply

MarketGladiator Jun. 23 at 12:08 AM

My position in $SLV $ABBV $NASA $LKNCY $EBS is based on retail sentiment crowding. Volatility is expected, but the structure still looks intact.

0 · Reply

topstockalerts Jun. 22 at 11:15 PM

$ABBV I’m starting to think this story has another chapter.

0 · Reply

SuperGreenToday Jun. 22 at 10:38 PM

$ABBV Share Price: $229.96 Contract Selected: Jul 17, 2026 $230 Calls Buy Zone: $4.97 – $6.14 Target Zone: $8.05 – $9.84 Potential Upside: 53% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

WallStreetBulll Jun. 22 at 10:38 PM

Still holding $MSTR $ABBV $MXL $ACN. The market is pricing in long-term conviction holding, but I think the longer-term story is still developing.

0 · Reply

Market Cap	382.49B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	21.71
Forward PE	15.14
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	4,025,021
Avg Vol	6,162,082
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	86%
Beta	0.32
Analysts	Strong Sell
Price Target	$251.55